From the beginning, our goal was to establish a different model to our partnerships. We have signed seven collaboration agreements with high-profile biopharmaceutical partners, several of which are joint development deals that enable us to retain significant control of our development programs as well as participate in the future of these products. Our goal is to maximize the potential of our platforms and pipeline and leverage the broad applicability of our mRNA drug class in additional therapeutic areas beyond cancer.
To learn more about partnering, licensing, collaborations, partnerships, or for any scientific inquiries, please contact:
An der Goldgrube 12